Loading the session
Loading the session
Loading instrument
$12.75
+2.08%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −23.1% (SPY −1.6%, XLV +13.5%). 3 months: −29.1% (SPY −0.4%, XLV +15.5%). 1 year: +68.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CGEM, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 decline of 20.7% was 6.2× its average daily move of 3.3% over the past year, and its largest one-day decline since 23 Sep 2026.
Daily closes, split-adjusted · as of 4 Nov 2026
7.6M shares were sold short at the 15 Oct 2026 settlement, 11.9% of the 64.4M shares outstanding; covering them would take 8.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
4 Nov 2026 volume of 2.2M shares was 2.3× the average of the 30 sessions before it (970.8K), as the price fell 20.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
The 4 Nov 2026 close of $12.49 was 28.4% below its 50-day average ($17.44) and 21.3% below its 200-day average ($15.86). It has closed below the 200-day for 18 sessions, since 12 Oct 2026. The 50-day average crossed above the 200-day on 2 Dec 2025, 232 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
November 24, 2025
+36.54%April 26, 2024
+31.43%May 12, 2022
+23.12%